Basel, Switzerland – 31 May 2023, Alentis Therapeutics (“Alentis”), the Claudin-1 company, today announced its participation in the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 2-6 in Chicago, IL, and the BIO International Convention to be held June 5-8 in Boston, MA. Alentis management will be present at the conferences. In case you want to schedule a meeting please reach out via info@alentis.ch. About Alentis Therapeutics Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is…

The grant supports the development of ALE.C04 for Claudin-1 positive tumors Basel, Switzerland – 9 May 2023, Alentis Therapeutics (“Alentis”), the Claudin-1 company, today announced it has been selected to receive a CHF 2.4M grant from the Swiss Accelerator project to further the development of ALE.C04 for Claudin-1 (CLDN1) positive cancers.Of the original 752 applications, the Innosuisse Innovation Council selected 53 projects to receive funding across multiple industries with significant innovation potential. The total funding granted amounts to CHF 112M.“We thank the Innosuisse Innovation Council for recognising Alentis’ work in oncology, and congratulate our fellow winners,” said Dr. Roberto…

The trial confirms ALE.F02’s good safety profile, exposure and target biological activity Basel, Switzerland – 26 April 2023,  Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced results from the multiple-ascending dose (MAD) part of its first-in-human Phase 1 clinical study of ALE.F02 targeting Claudin-1 (CLDN1).The trial enrolled 24 subjects: 18 received the active drug and six received placebo across three dose levels. Participants were dosed every two weeks.Dr. Luigi Manenti, Chief Medical Officer at Alentis said: “This study is the first to target CLDN1 in humans. ALE.F02 showed good…

CLAUDIN-1 targeting antibody ALE.C04 drives single agent activity and restores anti-PD1 efficacy in solid tumors Basel, Switzerland, April 14, 2023 – Alentis Therapeutics, the Claudin-1 company, today announced that Alberto Toso, Alentis’ SVP Head of Oncology, will present at the American Association for Cancer Research Conference in Orlando, Florida on April 18th.The poster session entitled, CLAUDIN-1 targeting antibody ALE.C04 drives single agent activity and restores anti-PD1 efficacy in solid tumors, presents evidence that ALE.C04 is a highly specific humanized monoclonal antibody that recognizes a unique CLDN1-exposed epitope in different solid tumors.Non-Junctional Claudin-1 (NJ-CLDN1) is frequently overexpressed in solid tumors.…

Basel, Switzerland – 13 April 2023, Alentis Therapeutics (“Alentis”), the Claudin-1 (CLDN1) company, is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. Today, Alentis announced $105 million in Series C financing. The funding round was led by Jeito Capital together with Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital.

Alentis ‘Shares Their Colors’ for ANCA-Associated Glomerulonephritis and Idiopathic Pulmonary Fibrosis Basel, Switzerland – 28 February 2023Rare Disease Day takes place annually on the last day of February to raise awareness for the more than 7,000 rare diseases and their impact on patients’ lives. Physicians, patients, patient advocates, researchers and medical & biotech companies from around the world shine a light on these little-known diseases and champion the need for education, research funding and access to treatment.Alentis has chosen to spread the word through a team event showing support for patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis and Idiopathic…

Alentis names Markus Meyer COO and promotes Alberto Toso to SVP Head Oncology and Geoffrey Teixeira to SVP Head Fibrosis Basel, Switzerland – 17 February 2023 Alentis Therapeutics (“Alentis”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced the appointment of Markus Meyer to Chief Operations Officer (COO), Geoffrey Teixeira to SVP Head Fibrosis, Alberto Toso to SVP Head Oncology, effective 15 February.In his new role, Markus will be responsible for leading the development of Alentis’ portfolio of monoclonal antibodies that are highly selective in targeting exposed and non-junctional Claudin-1 (CLDN1). Alentis’ pipeline includes…

Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1) F02 found to be well tolerated at all doses with a good safety profile and demonstrated initial evidence of on-target biological activity Planned initiation of first-in-human clinical study for lead oncology asset ALE.C04 in H2 2023 Basel, Switzerland – 9 January 2023 Alentis Therapeutics (“Alentis”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announces positive results from a single ascending dose Phase 1 study of its lead program, ALE.F02, currently in development for the treatment of advanced kidney,…

Basel, Switzerland – 5 January 2023 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced the appointment of Dr. Luigi Manenti as Chief Medical Officer (CMO).In his new role, Dr. Manenti will be responsible for leading the development of Alentis’s portfolio of monoclonal antibodies that are highly selective in targeting exposed and non-junctional Claudin-1 (CLDN1). Alentis’s pipeline includes ALE.F02, which is currently in Phase 1 clinical studies for the treatment of advanced kidney, liver and lung fibrosis; and ALE.C04, currently at IND submission stage to treat CLDN1+ solid…

Important data provide further validation of Alentis’ approach to develop first-in-class anti-Claudin-1 monoclonal antibodies to treat advanced fibrosis and fibrotic cancersBasel, Switzerland – 21 December 2022 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and fibrotic-associated cancers, today announces that Scientific Founder Professor Thomas Baumert’s team has published an article in the peer-reviewed journal Science Translational Medicine providing preclinical proof-of-concept for Claudin-1-specific monoclonal antibodies for the treatment of fibrosis and cancer prevention across organs.Severe tissue fibrosis is a key driver of end-stage organ failure and cancer, overall accounting for up to 45%…